Arsenic trioxide: An anti cancer missile with multiple warheads

References

• Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As203) in the treatment of acute promye-locytic leukemia: As203 induces NB4 cell apoptosis with downregulation of Bc1-2 expression and modulation of PML—RAR alpha/PML proteins. Blood 1996;88:1052–1061.
   PubMed Web of Science ®Google Scholar
• Mervis J. Ancient remedy performs new tricks. Science 1996;273:578–582.
   PubMed Web of Science ®Google Scholar
• Look AT. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia. J Natl Cancer Inst 1998;90:86–88.
   PubMed Web of Science ®Google Scholar
• Gallagher RE. Arsenic—new life for an old potion. N Engl J Med 1998;339:1389–1391.
   PubMed Web of Science ®Google Scholar
• Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell Jr., RP. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341–1348.
   PubMed Web of Science ®Google Scholar
• Warrell Jr., RP. Arsenicals and inhibitors of histone deacetylase as anticancer therapy. Haematologica. 1999;84:75–77.
   PubMedGoogle Scholar
• Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC, Bishop JM, de The H. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999;189:1043–1052.
   PubMed Web of Science ®Google Scholar
• Tamm I, Paternostro G, Zapata JM. Treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1999;40:1043, discussion 1044–1045.
   Google Scholar
• Hu J, Shen ZX, Sun GL, Chen SJ, Wang ZY, Chen Z. Long-term survival and prognostic study in acute promyelo-cytic leukemia treated with ATRA, chemotherapy, and As203: An experience of 120 patients. Int J Hematol 1999;70:248–260.
   PubMed Web of Science ®Google Scholar
• Slack JL, Rusiniak ME. Current issues in the manage-ment of acute promyelocytic leukemia. Ann Hematol 2000;79:227–238.
   PubMed Web of Science ®Google Scholar
• Wang ZY, Chen Z. Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia. Lancet Oncol 2000;1:101–106.
   PubMedGoogle Scholar
• Chen Z, Chen GQ, Shen ZX, Chen SJ, Wang ZY. Treatment of acute promyelocytic leukemia with arsenic compounds: In vitro and in vivo studies. Semin Hematol 2001;38: 26–36.
   PubMed Web of Science ®Google Scholar
• Cohen MH, Hirschfeld S, Susan FH, Ibrahim A, Johnson JR, O'Leary JJ, White RK, Williams GA, Pazdur R. Drug approval summaries: Arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist 2001;6: 4–11.
   PubMed Web of Science ®Google Scholar
• Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RI\4, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutre S, Dahlberg S, Ellison R, Worrell Jr, RP. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Chin Oncol 2001;19:3852–3860.
   Google Scholar
• Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, Chen Z. Arsenic trioxide, a therapeutic agent for APL. Oncogene 2001;20:7146–7153.
   PubMed Web of Science ®Google Scholar
• Mayorga J, Richardson-Hardin C, Dicke KA. Arsenic trioxide as effective therapy for relapsed acute promyelocytic leukemia. Chin J Oncol Nurs 2002;6:341–346.
   PubMedGoogle Scholar
• Tallman MS, Nabhan C. Management of acute promyelo-cytic leukemia. Curr Oncol Rep 2002;4:381–389.
   PubMedGoogle Scholar
• Zhu J, Chen Z, Lallemand-Breitenbach V, de The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer 2002;2:705–713.
   Google Scholar
• Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: A single center experience. Am J Hematol 2002;70:292–299.
   PubMed Web of Science ®Google Scholar
• Chen Z, Chen GQ, Shen ZX, Sun GL, Tong JH, Wang ZY, Chen SJ. Expanding the use of arsenic trioxide: Leukemias and beyond. Semin Hematol 2002;39(2 Suppl. 1): 22–26.
   PubMed Web of Science ®Google Scholar
• Dombret H, Fenaux P, Soignet SL, Tallman MS. Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin Hematol 2002;39(2 Suppl. 1):8–13.
   PubMed Web of Science ®Google Scholar
• Au WY, Chim CS, Lie AK, Liang R, Kwong YL. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Br J Haematol 2002;117:130–132.
   PubMed Web of Science ®Google Scholar
• Huan SY, Yang CH, Chen YC. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: A useful salvage therapy. Leuk Lymphoma 2000;38:283–293.
   Google Scholar
• Munshi NC, Tricot G, Desikan R, Bathos A, Zangari M, Toor A, Morris C, Anaissie E, Barlogie B. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 2002;16:1835–1837.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Zwiebel JA, Dancey J, Murgo A. Novel therapeutic agents for the treatment of myelodysplastic syndromes. Semin Oncol 2000;27:560–577.
   PubMed Web of Science ®Google Scholar
• Vuky J, Yu R, Schwartz L, Motzer RJ. Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Investig New Drugs 2002;20:327–330.
   PubMed Web of Science ®Google Scholar
• Shen GL, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As203) in the treatment of acute promye-locytic leukemia: As203 induces NB4 cell apoptosis with downregulation of Bc1-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996;88:1052–1061.
   PubMed Web of Science ®Google Scholar
• Gianni M, de The H. In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contempora-neously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies. Leukemia 1999;13:739–749.
   PubMed Web of Science ®Google Scholar
• Rego EM, He LZ, Warrell RP, Jr, Wang ZG, Pandolfi PP. Retinoic acid (RA) and As203 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci USA 2000;97:10173–11018.
   PubMed Web of Science ®Google Scholar
• Sternsdorf T, Puccetti E, Jensen K, Hoelzer D, Will H, Ottmann OG, Ruthardt M. PIC-1/SUM0-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol 1999;19: 5170–5178.
   PubMed Web of Science ®Google Scholar
• Rojewski MT, Baldus C, Knout W, Thiel E, Schrezenmeier H. Dual effects of arsenic trioxide (As203) on non-acute promyelocytic leukaemia myeloid cell lines: Induction of apoptosis and inhibition of proliferation. Br J Haematol 2002;116: 555–563.
   PubMed Web of Science ®Google Scholar
• Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL,, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H, Chen SJ, Chen Z. Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): I. As203 exerts dose-dependent dual effects on APL cells. Blood 1997;89: 3345–3353.
   PubMed Web of Science ®Google Scholar
• Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W, Paolo Pandolfi P. The function of PML in p53-dependent apoptosis. Nat Cell Biol 2000;2:730–736.
   Google Scholar
• Warrell RP, Jr. Arsenicals and inhibitors of histone deacetylase as anticancer therapy. Haematologica. 1999;84: 75–77.
   PubMedGoogle Scholar
• Li J, Chen P, Sinogeeva N, Gorospe M, Wersto RP, Chrest FJ, Barnes J, Liu Y. Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells. J Biol Chem 2002;277:49504–49510.
   PubMed Web of Science ®Google Scholar
• Cai X, Yu Y, Huang Y, Zhang L, Jia PM, Zhao Q, Chen Z, Tong JH, Dai W, Chen GQ. Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia. 2003;17:1333–1337.
   PubMed Web of Science ®Google Scholar
• Cai X, Shen YL, Zhu Q Jia PM, Yu Y, Zhou L, Huang Y, Zhang JW, Xiong SM, Chen SJ, Wang ZY, Chen Z, Chen GQ. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial trans-membrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000;14:262–270.
   Google Scholar
• Jing Y, Dai J, Chalmers-Redman RI\4, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999;94:2102–2111.
   Google Scholar
• Davison K, Mann KK, Miller WH, Jr. Arsenic trioxide: Mechanisms of action. Semin Hematol 2002;39(2 Suppl. 1): 3–7.
   PubMed Web of Science ®Google Scholar
• Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999;93:268–277.
   PubMed Web of Science ®Google Scholar
• Miller WH, Jr. Molecular targets of arsenic trioxide in malignant cells. Oncologist 2002;7 (Suppl. 1):14–19.
   PubMedGoogle Scholar
• Miller WH, Jr., Waxman S. Differentiation induction as a treatment for hematologic malignancies. Oncogene 2002;21 (21) :3496–3506.
   PubMed Web of Science ®Google Scholar
• Gurr JR, Bau DT, Liu F, Lynn S, Jan KY. Dithiothreitol enhances arsenic trioxide-induced apoptosis in NB4 cells. Mol Pharmacol 1999;56(1) :102–109.
   PubMed Web of Science ®Google Scholar
• Kitamura K, Minami Y, Yamamoto K, Akao Y, Kiyoi H, Saito H, Naoe T. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia 2000;14: 1743–1750.
   PubMed Web of Science ®Google Scholar
• Verma A, Mohindru M, Deb DK, Sassano A, Kambhampati S, Ravandi F, Minucci S, Kalvakolanu DV, Platanias LC. Activation of Racl and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J Biol Chem 2002;277: 44988–44995.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP, Jr., Rafii S. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000;96:1525–1530.
   Google Scholar
• Gianni M, Koken MH, Chelbi-Alix MK, Benoit G, Lanotte M, Chen Z, de The H. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 1998;91: 4300–4310.
   PubMed Web of Science ®Google Scholar
• Kinjo K, Kizaki M, Muto A, Fukuchi Y, Umezawa A, Yamato K, Nishihara T, Hata J, Ito M, Ueyama Y, Ikeda Y. Arsenic trioxide (As203)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia 2000;14: 431–438.
   PubMed Web of Science ®Google Scholar
• Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC, Bishop JM, de The H. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999;189:1043–1052.
   PubMed Web of Science ®Google Scholar
• Muto A, Kizaki M, Kawamura C, Matsushita H, Fukuchi Y, Umezawa A, Yamada T, Hata J, Hozumi N, Yamato K, Ito M, Ueyama Y, Ikeda Y. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combina-tion of arsenic trioxide and GM-C SF. Leukemia 2001;15:1176–1184.
   PubMed Web of Science ®Google Scholar
• Bachleitner-Hofmann T, Gisslinger B, Grumbeck E, Gisslinger H. Arsenic trioxide and ascorbic acid: Synergy with potential implications for the treatment of acute myeloid leukaemia. Br J Haematol 2001;112:783–786.
   PubMed Web of Science ®Google Scholar
• Perkins C, Kim CN, Fang G, Bhalla KN. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bc1-2, or Bc1-xL. Blood 2000;95:1014–1022.
   PubMed Web of Science ®Google Scholar
• Shim MJ, Kim HJ, Yang SJ, Lee IS, Choi HI, Kim T. Arsenic trioxide induces apoptosis in CML K562 cells: Possible involvement of p38 MAP kinase. J Biochem Mol Biol 2002;35:377–383.
   PubMedGoogle Scholar
• Puccetti E, Guller S, Orleth A, Bruggenolte N, Hoelzer D, Ottmann OG, Ruthardt M. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Res 2000;60:3409–3413.
   PubMed Web of Science ®Google Scholar
• Larochette N, Decaudin D, Jacotot E, Brenner C, Marzo I, Susin SA, Zamzami N, Xie Z, Reed J, Kroemer G. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res 1999;249:413–421.
   PubMed Web of Science ®Google Scholar
• Park JW, Choi YJ, Jang MA, Baek SH, Lim JH, Passaniti T, Kwon TK. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bc1-2 phosphoryl-ation in promonocytic U937 cells. Biochem Biophys Res Commun 2001;6: 726–734.
   Google Scholar
• Iwama K, Nakajo S, Aiuchi T, Nakaya K. Apoptosis induced by arsenic trioxide in leukemia U937 cells is dependent on activation of p38, inactivation of ERK and the Ca2 + -dependent production of superoxide. Int J Cancer 2001;92:518–526.
   PubMed Web of Science ®Google Scholar
• Choi YJ, Park JW, Suh SI, Mun KC, Bae JH, Song DK, Kim SP, Kwon TK. Arsenic trioxide-induced apoptosis in U937 cells involve generation of reactive oxygen species and inhibition of Akt. Int J Oncol 2002;21:603–610.
   PubMed Web of Science ®Google Scholar
• Hu X14, Hirano T, Oka K. Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells. Cancer Chemother Pharmacol 2003;51: 119–126.
   PubMed Web of Science ®Google Scholar
• Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, Kim BK, Lee YY. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest and induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 2000;60:3065–3071.
   PubMed Web of Science ®Google Scholar
• Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez HF, Boise LH, Lee KP. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Chin Cancer Res 2002;8:3658–3668.
   Web of Science ®Google Scholar
• Gartenhaus RB, Prachand SN, Paniaqua M, Li Y, Gordon LI. Arsenic trioxide cytotoxicity in steroid and chemother-apy-resistant myeloma cell lines: Enhancement of apoptosis by manipulation of cellular redox state. Chin Cancer Res 2002;8:566–572.
   Google Scholar
• Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D, Munshi NC, Waxman S, Anderson KC. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenviron-ment. Mol Cancer Ther 2002;1:851–860.
   PubMed Web of Science ®Google Scholar
• Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH. Ascorbic acid enhances arsenic trioxide-induced cyto-toxicity in multiple myeloma cells. Blood 2001;98:805–813.
   PubMed Web of Science ®Google Scholar
• Liu Q, Hilsenbeck S, Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53 dependent G1 or G2/M cell cycle arrest, activation of caspase 8 or caspase 9 and synergy with AP02/Trail. Blood 2003;101: 4078–4087.
   PubMed Web of Science ®Google Scholar
• Akay C, Gazitt Y. Arsenic trioxide selectively induces early and extensive apoptosis via the AP02/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53. Cell Cycle 2003;2:358–368.
   PubMed Web of Science ®Google Scholar
• Akay C, Thomas C, Gazitt Y. Arsenic trioxide and paclitaxel induce apoptosis by different mechanism. Cell Cycle 2004;3:324–334.
   PubMed Web of Science ®Google Scholar
• Ora I, Bondesson L, Jonsson C, Ljungberg J, Porn-Ares I, Garwicz S, Pahlman S. Arsenic trioxide inhibits neuroblas-toma growth in vivo and promotes apoptotic cell death in vitro. Biochem Biophys Res Commun 2000;277:179–185.
   Google Scholar
• Akao Y, Nakagawa Y, Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 1999;455: 59–62.
   PubMed Web of Science ®Google Scholar
• Shen ZY, Shen J, Cai WJ, Hong C, Zheng MH. The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. Int J Mol Med 2000;5:155–158.
   PubMed Web of Science ®Google Scholar
• Shen ZY, Shen WY, Chen MH, Shen J, Cai WJ, Zeng Y. Mitochondria, calcium and nitric oxide in the apoptotic pathway of esophageal carcinoma cells induced by As203. Int J Mol Med 2002;9:385–390.
   PubMed Web of Science ®Google Scholar
• Shen ZY, Shen J, Li QS, Chen CY, Chen JY, Yi Z. Morphological and functional changes of mitochondria in apoptotic esophageal carcinoma cells induced by arsenic trioxide. World J Gastroenterol 2002;8:31–35.
   PubMed Web of Science ®Google Scholar
• Jiang X, Wong B, Yuen S, Jiang SH, Cho CH, Lai KC, Lin MC, Kung HF, Lam SK, Wong BC. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer 2001;93:916–920.
   Web of Science ®Google Scholar
• Zhang TC, Cao EH, Li JF, Ma W, Qin JF. Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer 1999;35: 1258–1263.
   PubMed Web of Science ®Google Scholar
• Siu KP, Chan JY, Fung KR Effect of arsenic trioxide on human hepatocellular carcinoma HepG2 cells: Inhibition of proliferation and induction of apoptosis. Life Sci 2002; 71:275–285.
   PubMed Web of Science ®Google Scholar
• Kito M, Akao Y, Ohishi N, Yagi K, Nozawa Y. Arsenic trioxide-induced apoptosis and its enhancement by buthio-nine sulfoximine in hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2002;291:861–867.
   PubMed Web of Science ®Google Scholar
• Woo SH, Park IC, Park MJ, Lee HC, Lee SJ, Chun YJ, Lee SH, Hong SI, Rhee CH. Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. Int J Oncolw 2002;21:57–63.
   PubMed Web of Science ®Google Scholar
• Seol JG, Park WH, Kim ES, Jung CW, Hyun JM, Lee YY, Kim BK. Potential role of caspase-3 and -9 in arsenic trioxide-mediated apoptosis in PCI-1 head and neck cancer cells. Int J Oncol 2001;18: 249–255.
   PubMed Web of Science ®Google Scholar
• Chun YJ, Park IC, Park MJ, Woo SH, Hong SI, Chung HY, Kim TH, Lee YS, Rhee CH, Lee SJ. Enhancement of radiation response in human cervical cancer cells in vitro and in vivo by arsenic trioxide (As203). FEBS Lett 2002;519:195–200.
   PubMed Web of Science ®Google Scholar
• Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB, Goker E. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Chin Cancer Res 2000;6:4957–4964.
   Web of Science ®Google Scholar
• Maeda H, Hon S, Nishitoh H, Ichijo H, Ogawa O, Kakehi Y, Kakizuka A. Tumor growth inhibition by arsenic trioxide (As203) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 2001;61: 5432–5440.
   PubMed Web of Science ®Google Scholar
• Pu YS, Hour TC, Chen J, Huang CY, Guan JY, Lu SH. Arsenic trioxide as a novel anticancer agent against human transitional carcinoma-characterizing its apoptotic pathway. Anticancer Drugs 2002;13:293–300.
   PubMed Web of Science ®Google Scholar
• Zhao S, Tsuchida T, Kawakami K, Shi C, Kawamoto K. Effect of As203 on cell cycle progression and cyclins D1 and B1 expression in two glioblastoma cell lines differing in p53 status. Int J Oncol 2002;21: 49–55.
   PubMed Web of Science ®Google Scholar
• Park WH, Cho YH, Jung CW, Park OJ, Kim K, Hyuck Im Y, Lee MH, Ki Kang W, Park K. Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun 2003;300: 230–235.
   PubMed Web of Science ®Google Scholar
• Chen GC, Guan LS, Hu WL, Wang ZY. Functional repression of estrogen receptor a by arsenic trioxide in human breast cancer cells. Anticancer Res 2002;22(2A):633–638.
   PubMed Web of Science ®Google Scholar
• Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, De Cesaris MG, Surico N, Malavasi F, Ferrero E. Arsenic trioxide and breast cancer: Analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat 2002;73:61–73.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Canella D, Baj G, Arnulfo A, Waxman S, Malavasi F. Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)0(3)) on myeloma cells. Leuk Res 2001;25:227–235.
   PubMed Web of Science ®Google Scholar
• Yuksel S, Saydam G, Uslu R, Sanli UA, Terzioglu E, Buyukececi F, Omay SB. Arsenic trioxide and methyl-prednisolone use different signal transduction pathways in leukemic differentiation. Leuk Res 2002;26:391–398.
   PubMed Web of Science ®Google Scholar
• Mak NK, Wong RN, Leung KN, Fung M. Involvement of tumor necrosis factor a (TNF-a) in arsenic trioxide induced apoptotic cell death of murine myeloid leukemia cells. Toxicol Lett 2002;135:79–87.
   PubMed Web of Science ®Google Scholar
• Chen F, Lu Y, Zhang Z, Vallyathan V, Ding M, Castranova V, Shi X. Opposite effect of NF-kappa B and c-Jun N-terminal kinase on p53-independent GADD45 induction by arsenite. J Biol Chem 2001;276: 11414–11419.
   PubMed Web of Science ®Google Scholar
• Bajenova O, Tang B, Pearse R, Feinman R, Childs BH, Michaeli J. RIP kinase is involved in arsenic-induced apoptosis in multiple myeloma cells. Apoptosis 2004;9:561–571.
   PubMed Web of Science ®Google Scholar
• Yi J, Gao F, Shi G, Li H, Wang Z, Shi X, Tang X. The inherent cellular level of reactive oxygen species: One of the mechanisms determining apoptotic susceptibility of leukemic cells to arsenic trioxide. Apoptosis 2002;7:209–215.
   Google Scholar
• Yeh JY, Cheng LC, Ou BR, Whanger DP, Chang LW. Differential influences of various arsenic compounds on glutathione redox status and antioxidative enzymes in porcine endothelial cells. Cell Mol Life Sci 2002;59:1972–1982.
   PubMed Web of Science ®Google Scholar
• Yang CH, Kuo ML, Chen JC, Chen YC. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 1999;81:796–799.
   PubMed Web of Science ®Google Scholar
• Huang XJ, Wiernik PH, Klein RS, Gallagher RE. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Med Oncol 1999;16:58–64.
   PubMed Web of Science ®Google Scholar
• Kroemer G, de The H. Arsenic trioxide, a novel mitochon-driotoxic anticancer agent? J Natl Cancer Inst 1999;91:743–745.
   PubMed Web of Science ®Google Scholar
• Adams JM, Cory S. The bc1-2 protein family: Arbiters of cell survival. Science 1998;281:1322–1326.
   PubMed Web of Science ®Google Scholar
• Halicka HD, Smolewski P, Darzynkiewicz Z, Dai W, Traganos F. Arsenic trioxide arrests cells early in mitosis leading to apoptosis. Cell Cycle 2002;1:201–209.
   PubMed Web of Science ®Google Scholar
• Mahieux R, Pise-Masison C, Gessain A, Brady JN, Olivier R, Perret E, Misteli T, Nicot C. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bc1-2 cleavage. Blood 2001;98:3762–3769.
   PubMed Web of Science ®Google Scholar
• Ling YH, Jiang JD, Holland JF, Perez-Soler R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol 2002;62:529–538.
   Google Scholar
• Scatena CD, Stewart ZA, Mays D, Tang LJ, Keefer CJ, Leach SD, Pietenpol JA. Mitotic phosphorylation of Bc1-2 during normal cell cycle progression and Taxol-induced growth arrest. J Biol Chem 1998;273: 30777–30784.
   PubMed Web of Science ®Google Scholar
• Li YM, Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 1999;59:776–780.
   PubMed Web of Science ®Google Scholar
• Cai X, Yu Y, Huang Y, Zhang L, Jia PM, Zhao Q, Chen Z, Tong JH, Dai W, Chen GQ. Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia 2003;17:1333–1337.
   PubMed Web of Science ®Google Scholar
• Li X, Ding X, Adrian TE. Arsenic trioxide induces apoptosis in pancreatic cancer cells via changes in cell cycle, caspase activation, and GADD expression. Pancreas 2003;27: 174–179.
   PubMed Web of Science ®Google Scholar
• Pan J, Xu G, Yeung SC. Cytochrome c release is upstream to activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel. J Chin Endocrinol Metab 2001;86: 4731–4740.
   PubMed Web of Science ®Google Scholar
• Yuan SY, Hsu SL, Tsai KJ, Yang CR. Involvement of mitochondrial pathway in Taxol-induced apoptosis of human T24 bladder cancer cells. Urol Res 2002;30:282–288.
   PubMed Web of Science ®Google Scholar
• Ofir R, Seidman R, Rabinski T, Krup M, Yavelsky V, Weinstein Y, Wolfson M. Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent. Cell Death Differ 2002;9: 636–642.
   PubMed Web of Science ®Google Scholar
• Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673–682.
   PubMed Web of Science ®Google Scholar
• Pitti RK, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by APO-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271: 12687–12690.
   PubMed Web of Science ®Google Scholar
• Marsters SA, Sheridan JP, Donahue J, Pitti RK, Gray CL, Goddard AD, Bauer KD, Ashkenazi A. Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-KB. Curr Biol 1996;6: 1669–1676.
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998;281:1305–1308.
   PubMed Web of Science ®Google Scholar
• Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of AP02/TRAIL-induced apoptosis in human melanoma. J Immunol 1998;161: 2833–2840.
   PubMed Web of Science ®Google Scholar
• Wu GS, Burns TF, McDonald 3rd, ER, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G, el-Deiry WS. KILLER/DR5 is a DNA damage-inducible, p53 regulated death receptor gene. Nat Genet 1997;17: 141–143.
   PubMed Web of Science ®Google Scholar
• Nagane M, Pan G, Weddle jj, Dixit VM, Cavenee WK, Huang HJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergis-tic cytotoxicity with tumor necrosis factor related apoptosis inducing ligand in vitro and in vivo. Cancer Res 2000;60:847–853.
   PubMed Web of Science ®Google Scholar
• Gliniak B, Le T. Tumor necrosis factor-related apoptosis inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 1999;59:6153–6158.
   PubMed Web of Science ®Google Scholar
• Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, Ross BD, Rehemtulla A. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 2000;97:1754–1759.
   PubMed Web of Science ®Google Scholar
• Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999;397:441–446.
   PubMed Web of Science ®Google Scholar
• Susin SA, Daugas E, Ravagnan L, Samejima K, Zamzami N, Loeffler M, Costantini P, Ferri KF, Irinopoulou T, Prevost MC, Brothers G, Mak TW, Penninger J, Earnshaw WC, Kroemer G. Two distinct pathways leading to nuclear apoptosis. J Exp Med 2000;192:571–580.
   PubMed Web of Science ®Google Scholar
• Ye H, Cande C, Stephanou NC, Jiang S, Gurbuxani S, Larochette N, Daugas E, Garrido C, Kroemer G, Wu H. DNA binding is required for the apoptogenic action of apoptosis inducing factor. Nat Struct Biol 2002;9:680–684.
   PubMedGoogle Scholar
• Ravagnan I, Gurbuxani S, Susin SA, Maisse C, Daugas E, Zamzami N, Mak T, Jäättelä M, Penninger JM, Garrido C, Kroemer G. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol 2001;3: 839–843.
   PubMed Web of Science ®Google Scholar
• Cande C, Cecconi F, Dessen P, Kroemer G. Apoptosis-inducing factor (AIF): Key to the conserved caspase-independent pathways of cell death? J Cell Sci 2002;115: 4727–4734.
   PubMed Web of Science ®Google Scholar
• Lipton SA, Bossy-Wetzel E. Dueling activities of AIF in cell death versus survival: DNA binding and redox activity. Cell 2002;111:147–150.
   PubMed Web of Science ®Google Scholar
• Woods DB, Vousden KH. Regulation of p53 function. Exp Cell Res 2001;264:56–66.
   PubMed Web of Science ®Google Scholar
• Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 2002;14:86–91.
   PubMed Web of Science ®Google Scholar
• Moll UM, Zaika A. Nuclear and mitochondrial apoptotic pathways of p53. FEBS Lett 2001;493:65–69.
   PubMed Web of Science ®Google Scholar
• Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 200120:1803-1815.
   PubMed Web of Science ®Google Scholar
• Schuler M, Green DR. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2002;29(Pt 6):684–688.
   Google Scholar
• Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activa-tion by eliminating IAP inhibition. Cell 2000;7(102):33–42.
   Google Scholar
• Henry H, Thomas A, Shen Y, White E. Regulation of the mitochondrial checkpoint in p53-mediated apoptosis confers resistance to cell death. Oncogene 2002;21:748–760.
   PubMed Web of Science ®Google Scholar
• La Rosee P, Johnson K, O'Dwyer ME, Druker BJ. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 2002;30:729–737.
   Google Scholar
• Porosnicu M, Nimmanapalli R, Nguyen D, Worthington E, Perkins C, Bhalla KN. Co-treatment with As203 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia 2001;15:772–778.
   PubMed Web of Science ®Google Scholar
• Lew YS, Kolozsvary A, Brown SL, Kim JH. Synergistic inter-action with arsenic trioxide and fractionated radiation in locally advanced murine tumor. Cancer Res 2002;62:4202–4205.
   PubMed Web of Science ®Google Scholar
• Chun YJ, Park IC, Park MJ, Woo SH, Hong SI, Chung HY, Kim TH, Lee YS, Rhee CH, Lee SJ. Enhancement of radiation response in human cervical cancer cells in vitro and in vivo by arsenic trioxide (As203). FEBS Lett 2002;519:195–200.
   PubMed Web of Science ®Google Scholar
• Lai YL, Chang HH, Huang MJ, Chang KH, Su WH, Chen HW, Chung CH, Wang WY, Lin LH, Chen YJ. Combined effect of topical arsenic trioxide and radiation therapy on skin-infiltrating lesions of breast cancer-a pilot study. Anticancer Drugs 2003;14:825–828.
   PubMedGoogle Scholar
• Raza A, Buonamici S, Lisak L, Tahir S, Li D, Imran M, Chaudary NI, Pervaiz H, Gallegos JA, Alvi MI, Mumtaz M, Gezer S, Venugopal P, Reddy P, Galili N, Candoni A, Singer J, Nucifora G. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelo-dysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res 2004;28:791–803.
   PubMed Web of Science ®Google Scholar
• Anderson KC, Boise LH, Louie R, Waxman S. Arsenic trioxide in multiple myeloma: Rationale and future direc-tions. Cancer J 2002;8:12–25.
   PubMed Web of Science ®Google Scholar
• Hussein MA, Saleh M, Ravandi F, Mason J, Rifkin RK, Ellison R. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol 2004;125: 470–476.
   PubMed Web of Science ®Google Scholar
• Borad MJ, Swift R, Berenson JR. Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma. Leukemia 2005;19:154–156.
   PubMed Web of Science ®Google Scholar
• Berenson JR, Swift RA, Ferretti D, Purner MB. A prospective, open-label safety and efficacy study of combi-nation treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma. Chin Lymphoma 2004;5:130–134.
   PubMedGoogle Scholar
• Campbell RA, Chen H, Zhu D, Santos JC, Bonavida B, Pang S, Said J, Berenson JR. Arsenic trioxide shows synergistic anti-myeloma effects when combined with bortezomib and melphalan in vitro and helps overcome resistance of multiple myeloma cells to these treatments in vivo. Blood 2004;102:p666A.
   Google Scholar